Ryoji Tominaga

Ryoji Tominaga

Auto-generated profile, based on publicly available information

Ryoji Tominaga

Department of Clinical Epidemiology, Graduate School of Medicine, Fukushima Medical University, Fukushima, Japan

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 June 2023 in Innovation in Aging
Verified
Journal Article
Open access
PDF file
STSei Takahashi
Sei Takahashi
TNToru Naganuma
Toru Naganuma
NKNoriaki Kurita
Noriaki Kurita
KOKenji Omae
Kenji Omae
TOTsuyoshi Ohnishi
Tsuyoshi Ohnishi
RTRyoji Tominaga
Ryoji Tominaga
Background and Objectives: The relationship between social isolation/loneliness and oral health is unclear. This study investigated the association between social isolation/loneliness and tooth loss in older Japanese adults. Research Design and Methods: This was a cross-sectional study of a population-based cohort (the Sukagawa Study); 5,490 cohort study participants aged ≥75 years and who were independent answered a self-administered questionnaire in 2018. Social isolation was defined based on the 6-item Japanese version of the Lubben Social Network Scale. Loneliness was measured by the 3-item Japanese version of the University of California, Los Angeles (UCLA) Loneliness Scale version 3. The primary outcome was tooth loss, defined as having fewer than 20 teeth. The secondary outcomes were decreased toothbrushing frequency and diminished ability to chew food. Prevalence ratios (PRs) were estimated using a modified Poisson regression analysis in 2 models—Model 1, which adjusted for age, gender, smoking status, alcohol consumption, low annual income, and short education period, and Model 2, which added history of depression, history of diabetes mellitus, history of stroke, and cognitive impairment to Model 1. Results: The primary analysis included 5,490 participants. Adjusted PRs of social isolation and loneliness for tooth loss (Model 1) were 0.97 (95% confidence interval [CI] 0.93–1.01) and 1.07 (95% CI 1.02–1.12), respectively; those for decreased toothbrushing frequency were 1.17 (95% CI 0.98– 1.39) and 1.59 (95% CI 1.30–1.93), respectively; and those for chewing difficulty were 1.65 (95% CI 1.12–2.43) and 3.01 (95% CI 2.02–4.51), respectively. The adjusted PRs in Model 2 demonstrated results similar to that of Model 1. Discussion and Implications: Loneliness is associated with tooth loss among older adults, whereas social isolation is not. Our findings can inform plans for policymakers, professionals, and organizations to identify lonely older adults and provide social prescriptions to improve their access to oral health care services.

13 September 2021 in European Spine Journal
Verified
Journal Article
Open access
PDF file
RTRyoji Tominaga
Ryoji Tominaga
NKNoriaki Kurita
Noriaki Kurita
YKYoshiyuki Kokubun
Yoshiyuki Kokubun
TNTakuya Nikaido
Takuya Nikaido
MSMiho Sekiguchi
Miho Sekiguchi
SKShin-Ichi Konno
Shin-Ichi Konno
Purpose: To determine whether abnormalities of the sagittal modifiers (SMs) of the Scoliosis Research Society (SRS)-Schwab classification truly reflect back pain (BP)-specific quality of life (QOL), it is necessary to examine their dose–response relationships and to determine clinically impactful thresholds for declines in BP-specific QOL. This study aimed to analyse the continuous dose–response relationship between each SM and BP-specific QOL. Methods: This cross-sectional study, using data from a Japanese population-based cohort study, included 519 community-dwelling residents aged ≥ 50 years who participated in the annual health examination. The participants completed the Roland–Morris Disability Questionnaire (RDQ) on BP-specific QOL. Spino-pelvic alignment based on SMs was assessed by whole-spine X-ray examinations. We fitted general linear models with or without nonlinear terms to estimate the dose–response relationship between each SM and BP-specific QOL. Results: Pelvic tilt, pelvic incidence minus lumbar lordosis (PI-LL), and sagittal vertical axis showed dose–response relationships with BP-specific QOL measured as the RDQ score. PI-LL was most likely to predict a minimally clinically important RDQ score when its value exceeded the 90th percentile. A nonlinear relationship between PI-LL and the BP-specific QOL score was found. RDQ increased when PI-LL exceeded 10°. Conclusion: PI-LL might be the most sensitive of the three modifiers of the SRS-Schwab classification for determining BP-specific QOL. Moreover, BP-specific QOL worsens rapidly when the compensatory mechanism against malalignment exceeds a critical value. Therefore, we suggest that traditional classifications and surgical strategies should be re-examined regarding the dose-dependent abnormalities of the SMs to develop a more reliable classification strategy.

13 September 2025 in Brain and Spine
Verified
Journal Article
Open access
MBMejdeddine Al Barajraji
Mejdeddine Al Barajraji
SBsami barrit
sami barrit
ABAdam Boukind
Adam Boukind
ATAlbert E Telfeian
Albert E Telfeian
Javier Quillo-OlveraJavier Quillo-Olvera
Javier Quillo-Olvera
NGNeurocore-SENSED Research Group
Neurocore-SENSED Research Group
Endoscopic spine surgery (ESS) has evolved considerably, yet there remains a lack of consensus on patient selection, technical specifications, and outcome reporting. This heterogeneity hinders collaborative efforts to establish comprehensive evidence-based practices. To develop core outcome sets (COS) and reporting guidelines for ESS for disc disease through an international consensus. We established a multidisciplinary, international expert panel through literature review and peer-to-peer recruitment. Between January and April 2025, we employed a three-round modified Delphi technique. Items spanned three domains: patient characteristics, practices and outcomes. Propositions endorsed by ≥ 75 % of participants were classified as 'strong' and included in the COS. Those with 50-75 % were reconsidered in the subsequent round, requiring ≥66 % for inclusion as 'moderate'. The panel consisted of 77 spine surgeons from Europe (61 %), Asia (14 %), and North America (13 %), with 58 completing all three rounds. Of 183 items (165 initially provided, 18 participant add-ons), agreement was reached on 99 items (82 strongly and 17 moderately). Key consensus elements included demographics, comorbidities, clinical complaints, imaging findings, surgical indications, technical parameters, and outcome measures such as pain scores, functional outcomes, and complications. We established the Neurocore-SENSED framework, comprising COS and reporting guidelines for ESS for disc disease. This consensus addresses fundamental heterogeneity in ESS research, complementing existing nomenclature and indication-specific guidelines. By enhancing consistency, comparability, and quality of ESS research, this framework aims to accelerate the development of evidence-based practices that optimize patient outcomes in this rapidly advancing field.

1 July 2024 in JBJS Open Access
Verified
Journal Article
Open access
TYTakeru Yokota
Takeru Yokota
KOKoji Otani
Koji Otani
YEYuji Endo
Yuji Endo
RTRyoji Tominaga
Ryoji Tominaga
TKTakuya Kameda
Takuya Kameda
YMYoshihiro Matsumoto
Yoshihiro Matsumoto
Background: Previous studies have recognized the potential of the Vertebral Bone Quality (VBQ) score for predicting fractures. However, these studies often have lacked longitudinal perspectives and have not focused on community populations. Our study aimed to enhance the predictive capacity of the VBQ score by investigating its correlation with new vertebral fractures (NVFs) that were detected 11 years later in a community-based cohort and by developing a comprehensive prediction model. Methods: This study was a population-based study conducted in the Minami-Aizu area in Fukushima Prefecture, Japan. One hundred and thirty participants voluntarily underwent T1-weighted magnetic resonance imaging (MRI) of the lumbar spine in 2004 and 2015. VBQ scores were ascertained from the 2004 scans. NVFs that occurred between 2004 and 2015 were detected based on a ≥20% reduction in vertebral height on the midsagittal sections of the MRI. Other predictors that were considered included age, sex, body mass index, smoking history, heart disease, cerebrovascular disease, respiratory disease, and existing vertebral fractures (EVFs). A logistic regression analysis was conducted. Results: The logistic regression analysis indicated that the VBQ score, age, sex, and EVFs were significant predictors of NVFs. The prediction model showed an area under the curve of 0.84, suggesting excellent discriminatory power. The calibration capacity was confirmed using the Hosmer-Lemeshow test. Conclusions: The VBQ score was significantly correlated with the long-term incidence of NVFs in a community population. The prediction model exhibited satisfactory discrimination and calibration capacities, highlighting the use of the VBQ score as a potential tool for long-term prediction of NVFs. Level of Evidence: Prognostic Level II. See Instructions for Authors for a complete description of levels of evidence.

15 March 2026 in Neurologia medico-chirurgica
Verified
Journal Article
Open access
PDF file
KKKyohei Kin
Kyohei Kin
RTRyoji Tominaga
Ryoji Tominaga
KTKento Takebayashi
Kento Takebayashi
HIHiroki Iwai
Hiroki Iwai
HIHirohiko Inanami
Hirohiko Inanami
HKHisashi Koga
Hisashi Koga
The optimal management of lumbar spinal canal stenosis with spondylolisthesremains controversial, particularly when choosing between decompression alone or decompression with fusion. Current evidence is based on conventional open or endoscopy-assisted surgeries, with limited data on full-endoscopic decompression. This study aimed to assess the impact of spondylolisthesis on outcomes after full-endoscopic laminotomy by evaluating back pain-related disability scores in patients with lumbar spinal canal stenosis, with and without spondylolisthesis. A retrospective analysis was conducted at Iwai Orthopaedic Hospital, Japan. Patients with lumbar spinal canal stenosis who underwent full-endoscopic laminotomy between January 2021 and December 2022 were included and categorized into those without spondylolisthesis and those with spondylolisthesis. Postoperative Oswestry Disability Index scores at 2 years were compared in the groups using multivariable linear regression, adjusting for confounding factors. Exploratory analyses were also conducted to identify factors affecting the Oswestry Disability Index in the patients with lumbar spinal canal stenosis with spondylolisthesis group. Statistical significance was set at p < 0.05. The study included 80 patients, with 40 in each group. Both groups showed improved postoperative Oswestry Disability Index. There was no significant association between spondylolisthesis and postoperative Oswestry Disability Index. However, cauda equina redundancy negatively affected postoperative Oswestry Disability Index improvement in the patients with lumbar spinal canal stenosis with spondylolisthesis group. Full-endoscopic laminotomy is an effective surgical option for lumbar spinal canal stenosis, leading to significant alleviation of disability and improvements in quality of life, regardless of spondylolisthesis. Full-endoscopic laminotomy may offer similar functional improvements regardless of the presence of low-grade spondylolisthesis, supporting its role as a less invasive alternative to fusion.

15 March 2024 in medRxiv
Verified
Preprint
Open access
PDF file
RTRyoji Tominaga
Ryoji Tominaga
TITatsuyoshi Ikenoue
Tatsuyoshi Ikenoue
RIRyosuke Ishii
Ryosuke Ishii
KNKakuya Niihata
Kakuya Niihata
TATetsuro Aita
Tetsuro Aita
NKNoriaki Kurita
Noriaki Kurita
Importance: Romosozumab, a novel anti-osteoporotic agent, confers marked improvement in bone mineral density; however, its cardiovascular safety remains a concern. Objective: To compare the cardiovascular safety of romosozumab to bisphosphonates in patients with osteoporosis. Design: A cohort study using a new-user, active comparator design. Setting: Medical facilities, including clinics and hospitals, visited by a wide range of populations in Japan that are covered by a commercial administrative claims database, collected from March 4, 2019 to August 31, 2021. Participants: Japanese adults aged ≥40 years who were diagnosed with osteoporosis or experienced a fragility fracture. Those who received romosozumab or bisphosphonates after the commercialization of romosozumab started in Japan (March 4, 2019) were included. Exposure: A new prescription of romosozumab or bisphosphonate (based on verification of a 180-day washout period). Main Outcomes and Measures: The primary outcome was the incidence rate of cardiovascular disease (consisting of myocardial infarction and stroke) within one year of prescription. Cardiovascular disease was identified by algorithms with a combination of diagnosis, medical procedure, and drug codes. Facility-level prescription preference for romosozumab was used as an instrumental variable, defined as the proportion of romosozumab prescribed at the patient’s facility within 90 days prior to the index date. Results: Of the 61,558 included prescriptions, 8,806 were for romosozumab and 52,752 were for bisphosphonates. The mean age of the romosozumab group was higher than that of the bisphosphonates group (80.5 vs. 78.3 years, respectively). The majority of patients were female (80.2 vs. 85.3%, respectively). The incidence of cardiovascular disease was 7.98 per 100 person-years for romosozumab versus 7.15 for bisphosphonates (unadjusted incidence rate ratio: 1.12 (95% confidence interval: 1.03-1.21)). An instrumental variable analysis using the two-stage residual inclusion method yielded a hazard ratio of 1.09 (95% confidence interval: 0.79-1.76) for romosozumab compared to bisphosphonates over one year. Conclusions and Relevance: In this large observational study, there was no definitive evidence of increased risk of cardiovascular disease associated with romosozumab use compared with bisphosphonates in patients with osteoporosis. These findings alleviate clinicians’ excessive concerns about the potential cardiovascular safety of romosozumab in treatment decision-making for osteoporosis.